The short version of synthetic peptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-20. Anything still debated is marked as such rather than presented as settled.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Two other militiamen were identified as supporters of Daniela Carneiro's campaign. One of them is Cristiano de Oliveira Gouveia, known as Babu, who in a video posted on a social network appears with a sticker displaying Daniela's number. In addition, Babu appears on stage at a rally alongside Daniela and other candidates during the October elections. The other is Eduardo Araújo, a Belford Roxo councilor who was suspended after being appointed municipal secretary of Sustainable Energy of Belford Roxo. Eduardo participated in campaign motorcades with Daniela. The Public Prosecutor's Office says he was responsible for preventing the arrest of other members of the gang. Daniela Carneiro denied such involvement, stating that she does not condone "any illicit act" and that it is up to the courts to "judge and punish"; she also stated that she received support from numerous voters from various municipalities during her campaign. Deputy Marcelo Freixo, who gained notoriety by presiding over the CPI das Milícias in Rio de Janeiro, was appointed president of Embratur, an agency subordinate to the Ministry of Tourism. When questioned about the relationship, Freixo said that "it was up to her [Daniela] to speak about it" and that "my relationship with her is very recent, but very good and full of dialogue".
==== Opioid receptor modulators ==== Buprenorphine depot (Brixadi; Buvidal; CAM-2038; CAM-2048) – μ-opioid receptor agonist, δ-opioid receptor agonist, κ-opioid receptor antagonist, and nociceptin receptor agonist – opioid-related disorders Buprenorphine extended-release (Atrigel buprenorphine; BUP-XR-Indivior; depot buprenorphine; RBP-6000; Sublocade; Subutex prolonged release) – μ-opioid receptor agonist, δ-opioid receptor agonist, κ-opioid receptor antagonist, and nociceptin receptor agonist – opioid-related disorders Buprenorphine/naloxone sublingual (naloxone/buprenorphine; Sai Bo Song; SCH-000484; Suboxone) – combination of buprenorphine (non-selective opioid receptor modulator) and naloxone (orally/sublingually inactive opioid receptor antagonist) – opioid-related disorders Methadone (Zoryon) – μ-opioid receptor agonist – opioid-related disorders Nalmefene (Revex) – μ-opioid receptor antagonist, κ-opioid receptor weak partial agonist – opioid overdose, alcoholism Nalmefene (CPH-101; JF-1; Lu AA36143; nalmetrene; NIH-10365; ORF-11676; Selincro; Soberal) – μ-opioid receptor antagonist, κ-opioid receptor weak partial agonist – alcoholism Nalmefene nasal spray (intranasal nalmefene; Indivior; OPNT-003; Opvee) – μ-opioid receptor antagonist, κ-opioid receptor weak partial agonist – opioid-related disorders Nalorphine (Lethidrone, Nalline) – μ-opioid receptor antagonist, κ-opioid receptor agonist – opioid overdose Naloxone injection (Evzio; naloxone auto injector) – opioid receptor antagonist – opioid-related disorders Naloxone intranasal spray (Rezenopy) – μ-opioid receptor antagonist – opioid-related disorders Naloxone intranasal spray (Kloxxado; naloxone nasal spray) μ-opioid receptor antagonist – opioid-related disorders Naloxone multidose nasal spray (AP-003; Narcan) – μ-opioid receptor antagonist – opioid-related disorders Naloxone nasal spray (-12; LT-20; LT-21; LT-22; Naloxon B; Narcan Nasal Spray; OPNT-001) – μ-opioid receptor antagonist – opioid-related disorders Naltrexone controlled-release (Vivitrex; Vivitrol; XL-NTX; XR-NTX; ALKS-6428) – opioid receptor antagonist – alcoholism, opioid-related disorders Naltrexone oral (Nalorex; Nemexin; Revia) – opioid receptor antagonist – alcoholism, opioid-related disorders Other opioids (opioid agonist therapy) (e.g., dihydrocodeinone, extended-release morphine) – μ-opioid receptor agonists – opioid use disorder Tianeptine (Coaxil; Stablon; Tatinol) – μ-opioid receptor agonist, other actions – alcoholism
In 1888 Friedrich Reinitzer examined the properties of various derivatives of cholesterol which now belong to the class of materials known as cholesteric liquid crystals. Previously, other researchers had observed distinct colour effects when cooling cholesterol derivatives just above the freezing point, but had not associated it with a new phenomenon. Reinitzer found that cholesteryl benzoate does not melt in the same way as most substances, but has two melting points. At 145.5 °C (293.9 °F) it melts into a cloudy liquid, and at 178.5 °C (353.3 °F) it melts again and the cloudy liquid becomes clear. The phenomenon is reversible. Reinitzer sought assistance to understand the phenomenon and, on 14 March 1888, he wrote to Otto Lehmann. They exchanged letters and samples. Lehmann examined the intermediate cloudy fluid, and reported seeing crystallites. Reinitzer's colleague Victor Leopold von Zepharovich also indicated that the intermediate "fluid" was crystalline. Reinitzer published his results, with credit to Lehmann and von Zepharovich, on 3 May 1888. By that time, Reinitzer had discovered and described three important features of liquid crystals (the term was coined by Lehmann in a 1904 monograph): the existence of two melting points, the reflection of circularly polarized light, and the ability to rotate the direction of polarized light. Reinitzer did not pursue the study of liquid crystals further, although in 1908 he had to defend his role in their discovery when Lehmann claimed the priority.
=== 2 February === According to a South Korean news report, North Korea was planning to send up to 500 military and police personnel to Russian-occupied Donbass after pulling back on a previous plan to send workers. Police stated that a Russian missile destroyed an apartment building in Kramatorsk, killing at least three people and injuring 20 others. EU officials visited Kyiv.
Sources: en.wikipedia.org
=== Midlands Black Rhino Conservancy === The Mid West Rhinos maintain close links with the Midlands Black Rhino Conservancy. The conservancy is made up of several adjoining farms that give free rein to a number of the severely endangered Black Rhino. Each year the Mid West Rhinos stage the Midlands Black Rhino Conservancy T20 tournament. The tournament has grown from humble beginnings and now boasts participating teams from South Africa and Zambia. The proceeds from the tournament and other fundraising activities go directly to the conservancy.
According to the 2022 census, Belize's population is 397,483. Belize's total fertility rate in 2023 was 2.010 children per woman. Its birth rate was 17.8 births/1,000 population (2022), and the death rate was 6.3 deaths/1,000 population (2022). A substantial ethnic-demographic shift has been occurring since 1980 when the Creoles, formerly a majority of the population, have become outnumbered by the Hispanic/Mestizo community due to many Creoles moving to the United States, as well as a rising Mestizo birth rate and migration from Latin America.
=== Evolutionary history === Genetic analysis of mitochondrial DNA shows the Komodo dragon to be the closest relative (sister taxon) of the Australian lace monitor (V. varius), with their common ancestor diverging from a lineage that gave rise to the crocodile monitor (Varanus salvadorii) of New Guinea. A 2021 study showed that during the late Miocene, the ancestors of Komodo dragons had hybridized with the common ancestor of Australian sand monitors (V. spenceri, V. gouldii, V. rosenbergi and V. panoptes). Fossils from across Queensland demonstrate that the Komodo dragon was once present in Australia, with fossils spanning from the Early Pliocene (~3.8 million years ago) to the Middle Pleistocene, with the youngest confirmed records of the species in Australia dating to at latest 330,000 years ago. In Australia, it coexisted with the even larger monitor species Varanus priscus also known as megalania, the largest terrestrial lizard ever. The oldest records of the Komodo dragon on Flores date to around 1.4 million years ago, during the Early Pleistocene. Additionally, Pleistocene fossils of Varanus found in Java and Timor may belong to the Komodo dragon.
Sources: en.wikipedia.org
==== Attachment and biofilm formation ==== Attachment is another important method for regulating algicidal activity, as it can elongate the duration of interactions between bacteria and algae. It was observed that the number of attached bacteria per diatom was positively correlated with the lysis rate of algal cells, and the lysis rate increased when attachment rates were elevated. Attachment can be strengthened through biofilm formation, which consists of extracellular polymeric substances (EPS), adhesins, and other components capable of aggregating cells together. Biofilms allow for elongated interactions between bacteria and algal cells, and maintain the exchange of nutrients and gases.
=== DCLRE1C mutation === DCLRE1C "Artemis" is a gene required for DNA repair and V(D)J recombination. A recessive loss-of-function mutation found in the Navajo and Apache population causes SCID and radiation intolerance.
TNF inhibitors and methotrexate appear to have similar effectiveness when used alone, and better results are obtained when used together. Golimumab is effective when used with methotraxate. TNF inhibitors may have equivalent effectiveness, with etanercept appearing to be the safest. Injecting etanercept, in addition to methotrexate twice a week, may improve ACR50 and decrease radiographic progression for up to 3 years. Abatacept appears effective for RA with 20% more people improving with treatment than without but long term safety studies are yet unavailable. Adalimumab slows the time for the radiographic progression when used for 52 weeks. However, there is a lack of evidence to distinguish between the biologics available for RA. Issues with the biologics include their high cost and association with infections, including tuberculosis. Use of biological agents may reduce fatigue. The mechanism of how biologics reduce fatigue is unclear.
=== Diet === People who follow the prescribed dietary treatment from birth may (but not always) have no symptoms. Their PKU would be detectable only by a blood test. People must adhere to a diet low in Phe for optimal brain development. Since Phe is necessary to synthesize most proteins, it is required for appropriate growth, but levels must be strictly controlled.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.